Bloomberg "Anywhere" Remote Login Bloomberg "Terminal" Request a Demo


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $19.93 USD
Change Today +0.67 / 3.48%
Volume 73.5K
OMED On Other Exchanges
As of 8:10 PM 09/2/15 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Paul J. Hastings

Chairman, Chief Executive Officer and President,OncoMed Pharmaceuticals, Inc.
AgeTotal Calculated CompensationThis person is connected to 190 board members in 6 different organizations across 11 different industries.

See Board Relationships
As of Fiscal Year 2014


Mr. Paul J. Hastings has been the Chief Executive Officer and President at OncoMed Pharmaceuticals, Inc. since January 2006 and has been its Chairman since August 2013. Mr. Hastings served as a Business Advisor at Valocor Therapeutics, Inc. He joined OncoMed in 2006. He has over 20 years of experience as a biotechnology and pharmaceutical industry executive. He served as the President and Chief Executive Officer of QLT Inc. from February 2002 to September 2005, where ...

Read Full Background

Corporate Headquarters*

800 Chesapeake Drive
Redwood City, California 94063

United States

Phone: 650-995-8200
Fax: 650-995-8600

Board Members Memberships*

Chairman, Chief Executive Officer and President
Lead Director, Chairman of Compensation Committee and Member of Nominating & Corporate Governance Committee
Director, Chairman of Compensation Committee and Member of Nominating & Corporate Governance Committee


University Of Rhode Island

Other Affiliations*

Annual Compensation*

Total Annual Compensation$469,480

Stock Options*

Restricted Stock Awards$698,175
Exercisable Options515,520
Exercisable Options Value$8,711,560
Unexercisable Options243,334
Unexercisable Options Value$573,070
Total Value of Options$9,284,629
Total Number of Options758,854

Total Compensation*

Total Annual Cash Compensation$704,220
Total Short Term Compensation$469,480
Other Long Term Compensation$698,175
Total Calculated Compensation$3,211,951
*Data is at least as current as the most recent Definitive Proxy.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
OMED:US $19.93 USD +0.67


There is no Competitor Compensation data available.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ONCOMED PHARMACEUTICALS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at